Crestline Management, LP Rigel Pharmaceuticals Inc Transaction History

Crestline Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$2.6 - $3.59 $1.73 Million - $2.39 Million	-664,917 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $1 Million - $1.46 Million	354,523 Added 114.22%	664,917 $1.88 Million
Q1 2018 May 15, 2018	SELL	$3.54 - $4.54 $261,283 - $335,092	-73,809 Reduced 19.21%	310,394 $1.1 Million
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $178,166 - $237,188	55,160 Added 16.76%	384,203 $1.49 Million
Q3 2017 Nov 14, 2017	SELL	$2.18 - $2.57 $310,977 - $366,610	-142,650 Reduced 30.24%	329,043 $836,000
Q2 2017 Aug 14, 2017	BUY	N/A	471,693	471,693 $1.29 Million

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.81B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.